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ABSTRACT. Bovine viral diarrhea virus (BVDV) is an economically important animal pathogen affecting cattle. 
Despite the use of vaccination, test and slaughter practices, BVD remains a serious problem of cattle breeding. This 
study was conducted in order to develop a cell line that expresses some of BVDV sub-replicons. BVDV-NADL NS3 
and 5’UTR were cloned in pWPI-linker B lentiviral plasmid at the upstream of EGFP gene. Consequently, lentiviral 
vectors containing BVDV-NS3 and BVDV-5’UTR were produced by using the second-generation lentiviral packaging 
system. By these lentivectors, MDBK cells expressing BVDV-5’UTR and BVDV-NS3 partial fragments were prepared. 
The efficiency of the infection was evaluated by fluorescence microscopy, western blotting, and RT-PCR. The results 
indicated that the development of MDBK cell line expressing these transgenes provides a very sensitive antiviral drug 
screening system for anti-bovine viral diarrhea virus (BVDV) therapies. 
Keywords: Packaging system, BVDV, Lentiviral vectors, Cell line.
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INTRODUCTION
Bovine viral diarrhea virus (BVDV) is one of the 
most important viral pathogens in cattle, causing 
economic losses all over the world. BVDV is an 
enveloped, positive sense, single stranded RNA 
virus that is classified in the genus pestivirus of 
Flaviviridae family (Li et al., 2010). BVDV can 
induce lifelong persistent infection in cattle 
populations (Li et al., 2010; Carmona et al., 2012), 
and it can lead to a severe disease involving the 
respiratory, enteric, reproductive, immune, and 
endocrine systems (Keyvanfar and Hemmatzadeh, 
2000; Hemmatzadeh et al., 2006; Lambeth et 
al., 2007). This virus has two biotypes which are 
termed cytopathic (cp) and non-cytopathic (ncp). 
Furthermore, based on the difference in the 
nucleotide sequences, it has two genotypes: BVDV-
1 and BVDV-2 (Spurgers et al., 2008; Khaliq et al., 
2010; Li et al., 2010). Although commercial BVDV 
vaccines are available, its antigenic diversity is one 
of the reasons for the relative failure in vaccination 
programs. In addition, despite the extensive use of 
eradication and slaughter strategies after screening 
tests, the disease caused by BVDV remains prevalent 
in cattle herds all over the world (Wilson et al., 2005; 
Khaliq et al., 2010; Li et al., 2010). 
BVDV genome is approximately 12 Kb in length 
and is flanked by a 3’ and a 5’ untranslated region 
(UTRs). The BVDV genome encodes a single open 
reading frame (ORF) with approximately 4000 codons 
(Houe, 2003; Henry et al., 2006; Zemke et al., 2010; 
Fan and Bird, 2012). This ORF encodes a poly-
protein precursor which can simultaneously or post-
translationally be cleaved by viral or cellular proteases 
to produce 12 or 13 proteins in the following order: 
NH2-Npro-C-Erns-E1-E2-p7-NS2-NS3 (NS23)-
NS4A-NS4B-NS5A-NS5B-COOH.
NS3 is known as a cp-BVDV marker with serine 
protease activity. Its cleavage sites in the genome of 
the virus are the following: NS3/NS4A, NS4A/NS4B, 
NS4B/NS5A, and NS5A/NS5B. Moreover, NS3 has 
RNA helicase and nucleoside three trihosphatase 
activities. The expression of NS3 or NS23 is 
necessary for the formation of infectious virions. The 
MAŚLANKA T., ZUŚKA-PROT M.
protease activity of NS3 can induce apoptosis in the 
infected cells (Xu et al., 1997; St-Louis et al., 2005; 
Pankraz et al., 2009). 
The 5’UTR region with 370 b length, is the most 
conserved region of the viral genome, and it includes 
an internal ribosome entry sequence (IRES). The 
nucleotide sequence and secondary structures of 
5’UTR is important for the translation of ORF, the 
regulation of gene transcription, and the expression of 
genes associated with the virulence of BVDV (Poole 
et al., 1995).
Considering the specific functional role of these 
two parts of BVDV genome, we produced a cell line, 
after the insertion of these parts, in order to evaluate 
the therapeutic strategies against this virus (Henry et 
al., 2006).
For that purpose, in this study, lentiviral vectors 
expressing NS3and 5’UTR were produced by 
second-generation lentivirus packaging system, to 
infect Madin-Darby bovine kidney (MDBK) cells, 
permanently.
During their life cycle, lentiviruses can integrate 
their genomes into the host genome; therefore, they 
can be suitable tools for long-term expression of a 
transgene. Lentiviral vectors are modified so that 
only a limited number of lentiviral genes are required 
for the engineered viral vectors. Furthermore, the 
stable integration of viral DNA into the host genome 
can be provided by these essential genes. By this 
strategy, the desired recombinant gene can be 
expressed frequently, but the infectious virus cannot 
be produced. To create such a lentiviral vector, one 
of the newest methods is the cloning of the essential 
genes of lentivirus and the transgenes in three or four 
different plasmids. Consequently, the co-transfection 
of these plasmids can produce a lentivector in a host 
cell line. 
Due to the persistent lentiviral vector infection and 
its ability to enter different cell lines (Salmon and 
Trono, 2006), in the present study, we employed 
these vectors for the production of MDBK cell lines 
to express BVDV NS3 partial genes and BVDV 
5’UTR. That system has been tested by our group for 
BVDV gene therapies (unpublished data).
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MATERIALS AND METHODS
Cloning of BVDV NS3 and BVDV 5’UTR in pWPI-
Linker B lentiviral vector
2.1.1- RT-PCR 
BVDV was inoculated in Bovine testicular cell 
line (BT). BT cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (GIBCO, 
America, Catalog No. 116- 12800) supplement-
ed with 10% fetal bovine serum (FBS) (GIBCO, 
America, Catalog No. 106- 10270) and 1x penicillin 
streptomycin (Sigma, America Catalog No. 116- 
12800). Cultures were incubated for 24 hours at 
37 ºC with 5% CO2. Consequently, BVDV-NADL 
(NC-001461) from the Sekans animal health labo-
ratory, Ankara University (a generous gift from Dr. 
Faraji) inoculated to BT cells. RNA was isolated 48 
h after BVDV infection using QIAzol (QIAGEN, 
Germany, Catalog Number: 79306) according to 
the manufacturer’s instructions. One microgram of 
total RNA was reverse-transcribed with TaqMan 
Reverse Transcription kit (Invitrogen, Germany, 
Catalog Number: 8080234N) according to the man-
ufacturer’s instructions. PCR was carried out using 
the primers designed for apart of NS3 gene (3790- 
4000) and 5’UTR (first 386 nucleotides (of BVDV-
NADL (ac.no: NC00146). The sequences of primers 
were as follows: BVDV NS3 F: 5’-CGC CAC A GA 
TCT ACC GC AAG AGT ACT GG GGA A-3’and 
BVDV NS3  R: 5’-CGC CAC AGA TCT ACC 
CA TCA GTA GG TTA TAG TC-3’ with BglII 
restriction sites. BVDV 5’UTR F: 5’- CGC GGA 
TCC ACC A CTCGTAT ACG TAT TGG GC -3’ 
with BamHI restriction site and BVDV 5’UTR R: 
5’- GTT CCCCGG GC GT CCA TGT ACA CA 
GAG AT -3’ with SmaI site. The PCR thermal cycle 
reactions were consisted of denaturation at 95 º C 
for 30 s followed by 30 cycles at 95 º C for 15 s, 
68 º C (for NS3) and 69 º C (for 5’UTR) for 35 s 
and 72 º C for 40 s, followed by a final extension 
at 72 º C for 5 minutes. The positive and negative 
controls prepared from Animal Health Veterinary 
Laboratories Agency (AHVLA) (a generous gift 
from Dr. Steinbakh and Dr. Dastjerdi) were used in 
each test. 
Restriction enzyme digestion, ligation and colony 
PCR
The pWPI-Linker B lentiviral Plasmid had 
been prepared by the Research Center for Bio-
Medical (IMIM) in Spain (a generous gift from 
Fabien Delaspre) and digested by BamHI (Roche, 
Germany, Catalog Number: 10220612001) and 
SmaI  (Roche,  Germany,  Catalog Number: 
10220566001) for cloning of 5’UTR. This plasmid 
had been also digested by BamHI for cloning of 
NS3. Therefore, 1 μl of 1 μg / μl plasmid, 1μl 
enzyme, 2 μl 10x enzyme buffer and nuclease-
free water were used in a 20 μl reaction, after 
overnight incubation at 37 º C for single digestion 
and 20 º C for double digestion. Ligation reaction 
was performed with 2μl of T4 10x ligation buffer 
(Fermentas, Germany, Catalog Number: B69), 2μl 
of PEG-4000 50% (Fermentas, Germany), 1 μl 
of T4 DNA ligase (Fermentas, Germany, Catalog 
Number: EL0013), 150 ng of the inserting DNA 
and nuclease-free water up to 20μl. Then ligation 
products were transformed separately in the 
appropriate competent cell (Stbl4) by heat shock 
protocol. Briefly, 10 μl of ligation product was 
added to 100 μl of Stbl4, and the mixture was 
incubated for 30 minutes at 4 °C, 90 seconds at 
42 °C and 5 min at 4 ° C. Consequently, 900 μl of 
LB medium was added and shaked at 200 rpm for 
45 minutes. After centrifugation at 6000 rpm for 3 
min, the pellet was cultured in LB agar with 100 mg 
/ ml ampicillin. Plates were incubated at 37 ºC for 
16-14 hours. In order to determine the presence or 
absence of the inserted DNA in plasmid constructs, 
10 individual colonies from each plate were 
selected for PCR reaction and extraction of plasmid 
by using Mini preparation of DNA method. After 
electrophoresis in 0.8% agarose, the recombinant 
plasmids were sent for sequencing.
Lentiviral transduction of MDBK cells
The second-generation lentivirus packaging system 
(Addgene cat no. 12260 and 12259) was used to 
generate BVDV NS3 and BVDV 5´UTR lentiviruses. 
Briefly, 293Tcells (3×106 cells per10 cm dish) 
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were co-transfected with a mixture of 4 μg of 
pMD2.G plasmid encoding the vesicular stomatitis 
virus glycoprotein (VSV-G) envelope, 7.5 μg 
of the psPAX2 packaging plasmid, 11 μg of the 
BVDV NS3 - pWPI-Linker B and BVDV 5’UTR 
- pWPI-Linker B, using calcium phosphate-DNA 
precipitate method. The following day, the medium 
was replaced with 7ml of DMEM (Invitrogen) 
and further cultured for 72h. The supernatant was 
collected 48h and 72 h after transfection, cleared 
by centrifugation (3000 rpm, 15 min) and it was 
kept in -70 °C until the infection of MDBK cells. 
For the titration of the produced BVDV NS3 and 
BVDV-5´UTR lentiviral particles, the 293T cells 
(3×105 cells per each well of a 6-well plate) were 
transduced by 1 ml of suspensions containing these 
lentiviral particles. Then, the cells were analyzed 
for eEGFP expression using fluorescent microscopy 
and the viral titer was calculated. Consequently, 105 
trypsinized MDBK cells were infected in a 6-well 
plate by lentiviral vectors (MOI = 0.8), diluted 
in 1ml of DMEM medium supplemented by 10% 
FBS and polyberene (8 μg/ml). The medium was 
replaced with 7ml of DMEM (Invitrogen) 12h after 
the infection. MDBK cells were examined 48 h 
and 72 h after infection, by using a fluorescent 
microscope.
RT- PCR to validate infection of MDBK cells 
To confirm the expression of BVDV-NS3and BVDV-
5’UTR in MDBK cells, RNA was isolated from 
infected cells and following treatment with DNase, 
RT- PCR was carried out using the designed prim-
ers. The sequences of primers were as follows: 
BVDV NS3 F: CAT AGG TAG GCG TGA CCC 
AAC -3’and BVDV NS3 R: 5’- TCA GTG ACC 
CTC AGT GCT GC -3’. BVDV 5’UTR F: 5’- AGG 
GTA GTC GTC AGT GGT TC -3’ with and BVDV 
5’UTR R: 5’- AGG TTA AGA TGT GCT TTG 
GG -3’. The PCR materials and methods were the 
same with the ones described in section 2.1.1. The 
RT-PCR thermal cycle programs were consisted 
of denaturation at 95 º C for 2 min, followed by 30 
cycles at 95 º C for 30 s, 60 º C (for NS3) and 55 º C 
(for 5’UTR) for 30 s and 72 º C for 30 s, including 
a final extension step at 72 º C for 5 minutes. The 
positive (MDBK infected with BVDV) and negative 
(MDBK cells without any infection) controls  were 
employed in each test. 
Western blotting
For western blotting analysis, protein extracts were 
prepared from cell cultures in lysis buffer (50 mM 
Tris–HCl pH = 8.0, 150 mM NaCl, 2 mM EDTA, 
1% NP-40, 0.5% sodium deoxycholate, 1% SDS,1 
mM PMSF) for 20 min on ice. Protein extracts from 
positive and negative controls (MDBK cells infected 
with BVDV- NADL and MDBK cells without any 
lentiviral vector, respectively) were extracted too. 
All samples were vortexed for 10 min. Samples 
were centrifuged at 1000 g for 10 min at 4 ◦C. After 
Bradford and Lowry protein assay, 50 μg from the 
supernatant were added to sample buffer (Tris-HCl 
62.5 pH = 6.8 mM, 15% SDS, 0.01% Bromophenol 
blue, 10% glycerol, mercaptoethanol 25%, water), 
boiled for 3 min and loaded in polyacrylamide 
Resolving [3.5 mL of Deionized water, 4.0 mL 
of 30% acrylamide:bis-acrylamide (29:1), 2.5 mL 
of 1.5 M Tris-HCl, 0.4% SDS, pH 8.8, 100 µL of 
10% ammonium persulfate and 10 µL TEMED] 
and Stacking [2.1 mL of Deionized water, 0.63 mL 
of 30% acrylamide:bis-acrylamide (29:1), 1 mL 
of 0.5 M Tris-HCl, 0.4% SDS, pH 6.8, 30 µL of 
10% ammonium persulfate and 7.5 µL TEMED] 
SDS - PAGE gels and then electrophoresed. After 
SDS-PAGE, proteins were transferred to PVDF 
membranes. Viral proteins were detected with a 
mouse anti BVDV-NS3 monoclonal antibody (1:100) 
(Santa Cruz, America, Catalog Number: 101592sc) 
and rabbit anti-mouse IgG antibody conjugated 
with HRP (Santa Cruz, America, Catalog Number: 
358914sc-) (1:10 000). As a positive cellular 
control, alpha tubulin was detected with primary 
anti alpha tubulin mouse monoclonal antibody 
(Sigma, America, Catalog Number: 9026T). To 
develop Western blot, we used an ECL detection 
system (Amersham, Piscataway, NJ) according to the 
manufacturer’s directions. 
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RESULTS
RT-PCR 
The presence of BVDV- 5’UTR and BVDV- NS3 
fragments was detected using RT-PCR. Positive PCR 
products and positive control sample in the PCR test 
for detecting BVDV- NS3, were in the size of 223 
bp, while the size of the BVDV- 5’UTR -specific 
band was 380 bp. The validity of pWPI- Linker B 
digestion was tested by electrophoresis in 1% agarose 
gel (Fig 1).
Colony PCR
After the overnight incubation of the transformed 
Stbl4 as well as the controls (positive and negative) 
on plates containing LB agar + ampicillin at 37 ° C, 
recombinant plasmid containing colonies and positive 
control colonies (containing pWPI-LinkerB plasmid 
resistant to ampicillin that confirmed in previous 
experiments) were observed, while in the negative 
control plate (only Stbl4) there weren’t any colonies 
present.
The presence of BVDV- 5’UTR and BVDV- NS3 
fragments was detected in transformed colonies and 
positive control samples by using PCR (BVDV- 
NS3 bands were in the size of 223 bp, while the 
size of the BVDV- 5’UTR -specific band was 380 
bp) 
Fig 1. amplification of BVDV-NS3, BVDV – 5’UTR and 
digestion of pWPI-Linker B: Right: RT-PCR for amplifi-
cation of BVDV-NS3 and BVDV – 5’UTR after inocu-
lation of the virus into BT cell line: left to right: negative 
control for NS3, negative control for 5’UTR, 5’UTR 
band (380bp),Gene ruler(100bp), NS3  band(223bp).
Left: Single and double digestion of pWPI-Linker-B: left 
to right: double digestion of pWPI-Linker B, single diges-
tion of pWPI-Linker B, pWPI-Linker B, Gene ruler(1Kb)
Fig 2. Alignment of the NS3 sequence derived from sequencing with the desired amplicon.Left: Single and double 
digestion of pWPI-Linker-B: left to right: double digestion of pWPI-Linker B, single digestion of pWPI-Linker B, 
pWPI-Linker B, Gene ruler(1Kb)
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BVDV- NS3and BVDV- 5’UTR (Figs 2 and 3). 
entivirus production and infection
72 hours after transfection, the percentage of EGFP 
expressing 293 T cells was approximately 80-70%. 
That percentage suggested that the transfection effi-
After plasmid extraction from positive colonies, 
the validity of plasmid extraction and the presence 
of BVDV- NS3 and BVDV- 5’UTR fragments 
in the recombinant plasmids, were confirmed by 
digestion and electrophoresis. Sequence analysis of 
the recombinant plasmids revealed the presence of 
Fig 3. Alignment of the 5’UTR sequence derived from sequencing with the desired amplicon.
Fig 4. transfection of 293T cells with the lentiviral plasmids expressing the BVDV NS3 and BVDV 5’UTR
Right: EGFP levels observed after transfection of pWPI-Linker B-5’UTR in a second-generation lentiviral packaging system. 
Left: EGFP levels observed after transfection of pWPI-Linker B- NS3 in a second-generation lentiviral packaging system.
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ciency was appropriate for infection. By fluorescence 
microscopy observation, efficiency was also proved 
to be excellent (more than 90% EGFP expression). 
Thus, the MDBK cells infected with BVDV- NS3 
- lentivector and BVDV- 5’UTR- lentivector were 
considered as cell clones expressing BVDV NS3 
and BVDV 5’UTR (Figs 4-5).
RT- PCR to validate infection of MDBK cells
The expression of BVDV- 5’UTR and BVDV- NS3 
was detected in MDBK cells infected by lentiviral 
vectors expressing these transgenes and positive 
control (MDBK cells infected with BVDV) using 
RT-PCR tests (NS3 band: 87bp and 5´UTR band: 
68bp) (Fig 6).
Western blotting
Viral product was detected with rabbit anti mouse 
IgG against BVDV-NS3 (1:100). The specific 
band related to selected sequence of NS3 was 
approximately 15 KD. As loading control, alpha 
tubulin was detected with a mouse monoclonal 
antibody (1:1000) and its specific band was 55 KD 
(Fig 7).
Fig 5. Infection of MDBK cells with lentiviral vectors 
expressing BVDV NS3 and BVDV 5’UTR:
Images above: Right: EGFP expression after infection 
with lenti-vector carrying BVDV NS3 - Left: The same 
picture by using light microscopy.  
Images below: Right: EGFP expression after infection 
with lenti-vector carrying BVDV NS3 - Left: The same 
picture by using light microscopy.
Fig 6. RT-PCR to confirm the expression of BVDV 
5’UTR and BVDV NS3 in MDBK cells:
Left to right: MDBK-NS3, positive control: BVDV 
NS3, negative control for NS3, Gene ruler (100bp), 
MDBK 5’UTR, positive control: BVDV 5’UTR, nega-
tive control for5’UTR
Fig 7. Western blot to confirm the expression of BVDV 
NS3 in MDBK cells:
Top row: BVDV-NS3 band with the size of 80 kDa 
(left) and MDBK-NS3 serine protease as much as 
approximately 15 kDa (right) 
Bottom row: The 55 kDa band corresponding to alpha 
Tubulin in negative controls, positive controls (BVDV-
NS3) and test sample (MDBK-NS3) (left to right)
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survival, and virulence of the virus. In addition, 
for stable and long-term expression of the desired 
genes in the target cells, the lentiviral vector was 
utilized for transduction. Transfection of plasmid 
vectors has also been used by researchers to induce 
gene expression in the target cells, but with this 
method, the duration of gene expression is about 
4-10 days. Lentiviral vectors are specific types of 
retroviruses that can infect both dividing and non-
dividing cells because their pre-integration complex 
(virus “shell”) can get through the intact membrane 
of the nucleus of the target cell. Lentiviruses can be 
used to provide highly effective gene therapy, as 
they can change the expression of their target cell’s 
gene for up to six months. They can also be utilized 
for non-dividing or terminally differentiated cells, 
such as neurons, macrophages, hematopoietic 
stem cells, retinal photoreceptors, muscle and 
liver cells, to which the previous gene therapy 
methods could not be applied. Employing lentiviral 
vectors (LVs) offers multiple advantages for gene 
therapy, because they encompass the efficient 
delivery, the ability to transduce the proliferating 
and resting cells, the capacity to integrate into the 
host chromatin to provide the stable long-term 
expression of the transgene, the absence of any 
viral genes in the vector, and finally the absence 
of interference from pre-existing viral immunity. 
In addition, LVs can transfer large nucleotide 
sequences (3000 bp). As a result, they are preferred 
to other viral vectors such as adenoviral vectors, 
retroviral vectors, and AAVs. Moreover, due 
to the lower frequency of integration at or near 
the cellular proto-oncogenes, the possibility of 
mutagenesis and carcinogenesis as a result of gene 
induction by lentiviral vectors, is low (KuÈmmerer 
et al., 2000; Haga et al., 2006; Henry et al., 2006; 
Salmon and Trono, 2006; Tiscornia et al., 2006).
The genetic and antigenic diversity of BVDV 
is a major concern for the development and the 
efficacy of current vaccines. Thus, anti-BVDV 
drugs might be an alternative strategy to control 
BVD. Over the past decade, in vitro anti-BVDV 
therapies have been conducted on cell systems 
DISCUSSION
BVDV establishes a persistent infection in 
cattle populations worldwide, often resulting in 
significant economic impacts. Although the control 
measures for eradication, namely selective test and 
slaughter as well as vaccination, are widely used, 
BVDV remains prevalent due to its diversified 
antigenicity. The efficiency and the specificity of 
RNAi are attractive therapeutic characteristics that 
may prove useful for the development of antiviral 
therapies (Lambeth et al., 2007; Zemke et al., 
2010; Jordao et al., 2011). Constant changes in the 
antigenic regions of BVDV structure, particularly 
C, Erns, E1, and E2 antigens and the formation 
of scape mutants that evade the host immune 
response, have made the production of an effective 
vaccine difficult. The majority of BVDV vaccines 
are designed against the previously mentioned 
glycoproteins and proteins, and this is a crucial 
factor for the medium or low success to control 
or eradicate the disease (Meyers and Theil, 1996; 
Lambeth et al., 2007; Zemke et al., 2010; Jordao et 
al., 2011; Ni et al., 2012).
The aim of this study was to provide a suitable 
cell line expressing the genes of BVDV in order 
to evaluate the new antiviral treatment strategies, 
demonstrate their effectiveness and satisfy the 
methods for controlling or treating BVDV.
Gene therapies performed with the aim of 
antiviral treatments against Flaviviridae were 
targeted at almost all regions of the viral genome; 
however, due to the conservation of the 5’UTR 
sequences during the viral evolution and the critical 
tasks of NS2-3, NS3, NS5A, and NS5B, these 
parts have received more attention. Considering 
the previous studies with respect to the inhibitory 
efficacy of targeting each of these Flaviviral 
genomic sequences, NS3 and 5’UTR were selected 
for the cloning into lentiviral plasmid (Lv et al., 
2003; Randall et al., 2003, Randall et al., 2004; 
Lambeth et al., 2007; Gamlen et al., 2010).
Moreover, NS3 and 5’UTR were selected because 
of their conservation during virus evolution and due 
to their specific biological roles in cell proliferation, 
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takes time to design and produce this screening 
system accurately, and great bioinformatics and 
biotechnological knowledge are essential to prepare 
it. The selection of an appropriate insertion site for 
the marker gene is critical for the development of 
a recombinant reporter BVDV for antiviral drug 
screening, because the genotype and the phenotype 
of the recombinant virus should not be impaired 
by eEGFP or any other reporter gene insertion. 
Furthermore, the reporter gene must not affect the 
replication of the recombinant virus, which shows 
a same level of RNA and viral protein expression 
as the parent virus; in addition, the peak yield of 
progeny virus of the recombinant should not be 
less than the parent virus. The replication kinetics 
of the recombinant reporter BVDV and that of the 
parent virus should be similar. The reporter gene 
expression and its fluorescent signal intensity are 
correlated with the replication of the recombinant 
reporter BVDV. In many cases due to weaknesses 
in the design of monocistronic reporter virus, 
the fluorescence intensity is less than the amount 
approved for careful screening of antiviral drugs. 
Moreover, owing to the diversity and abundance of 
genetic changes that occur in the genome of RNA 
viruses, it is necessary to have the valid parent 
virus or its cDNA clone in order to produce the 
reporter virus (KuÈmmerer et al., 2000; Wilson 
et al., 2005; Carmona et al., 2012; Fan and Bird, 
2012). Because of the limitations and difficulties 
mentioned in the design and the production of 
recombinant monocistronic viruses, lentiviral 
vectors were utilized to induce the expression of 
target genes of BVDV. 
CONCLUSIONS
Therefore, in this study, MDBK cells expressing 
BVDV NS3 and BVDV 5´UTR were produced, 
using lentivector transduction. The results indicated 
that the development of MDBK cell line expressing 
these transgenes, acted very sensitive for anti-
BVDV therapies screening. That cell line has been 
tested by our group for gene therapies based on 
RNAi against BVDV (unpublished data).
with either sub-genomic replicon or infectious 
viral particle of BVDV as the target. The BVDV 
sub-genomic replicon contains only non-structural 
regions, and the anti-viral therapeutic intervention 
of the structural region of BVDV cannot be 
studied. As for the infectious viral particles of 
BVDV, the time-consuming, labor-intensive, 
quantitative reverse transcriptase PCR methods 
have to be applied. A screening tool targeting both 
structural and non-structural proteins of BVDV 
and supporting high through-put anti-BVDV 
drug screening can be a monocistronic reporter 
virus with an enhanced green fluorescent protein 
(eEGFP) as a marker. The positive-oriented, single-
stranded RNA viruses can be reconstituted, using 
reverse genetics strategy that provides a powerful 
tool for investigation of many aspects of the viral 
life cycle and pathogenesis. Numerous recombinant 
viruses and sub-genomic replicons have been 
generated by Flaviviridae family from viral cDNA 
clones and have been extensively employed as 
tools for antiviral drug screening. As for BVDV, 
efforts have been made by a few research groups 
to achieve a stable, easy-handling, reverse genetics 
system. Over the past decade, several milestones 
have been reached in the development of cell-
based generation of recombinant BVDV. For 
example, the employment of a Bacterial artificial 
chromosome (BAC) vector stabilizes the viral 
genome during the construct replication in bacteria. 
It was previously found that BVDV is a suitable 
viral vector for the expression of heterologous 
proteins such as eEGFP when inserted between 
viral Npro and capsid proteins. In the study done 
by Fan and Bird in 2012, a stable, reverse genetic 
system was created on the basis of an infectious 
BAC cDNA clone (pBSD1) that has an NCP 
BVDV strain SD-1 background. A recombinant 
reporter BVDV was produced, stably expressing 
eEGFP protein as inserted between viral NS3and 
NS4A proteins. Despite the huge advantages of 
monocistronic reporter BVDV for screening anti-
BVDV drugs, this screening system has some 
disadvantages and limitations as well. First, it 
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